MPO and non-small cell lung carcinoma: Lesion volume and maximum diameter had the highest predictive performance in response to treatment with Gefitinib for non-small-cell lung carcinoma patients (41), which indicated that the range and median of the lesion can predict treatment resistance for those MPO-AAV patients with lung involvement.